Summary: Treatment-Naive Genotype 1a Without Cirrhosis
Recommended and alternative regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 1a Patients Without Cirrhosis
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASsa for elbasvir
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b
|
8 weeks
|
I, A
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
|
12 weeks
|
I, A
|
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are non-black, HIV-uninfected, and whose HCV RNA level is <6 million IU/mL
|
8 weeks
|
I, B
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
|
12 weeks
|
I, A
|
|
ALTERNATIVE
|
DURATION
|
RATING
|
|
Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) as part of an extended-release regimen or plus twice-daily dosed dasabuvir (250 mg), with weight-based ribavirin
|
12 weeks
|
I, A
|
|
Daily simeprevir (150 mg) plus sofosbuvir (400 mg)
|
12 weeks
|
I, A
|
|
Daily daclatasvir (60 mg)c plus sofosbuvir (400 mg)
|
12 weeks
|
I, B
|
|
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) with weight-based ribavirin for patients with baseline NS5A RASsa for elbasvir
|
16 weeks
|
IIa, B
|
a Includes genotype 1a resistance-associated substitutions at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance.
b This is a 3-tablet coformulation. Please refer to the prescribing information.
c The dose of daclatasvir may need to be increased or decreased when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. Please refer to the prescribing information and the section on HIV/HCV coinfection for patients on antiretroviral therapy.
|
